CD274 and cervical carcinoma: Following the KEYNOTE-158 study, the Food and Drug Administration (FDA) approved pembrolizumab for the treatment of advanced cervical cancer on June 12, 2018, and it is recommended as a second-line treatment for PD-L1 positive cervical cancers that have progressed following chemoresistance, as well as in 2021 it has been approved as the first-line treatment for cervical malignancies (57).